会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • In Vitro Production Of Oligodendrocytes From Human Umbilical Cord Stem Cells
    • 从人脐带干细胞体外产生少突胶质细胞
    • US20120128639A1
    • 2012-05-24
    • US13322903
    • 2010-05-28
    • James J. HickmanHedvika Davis
    • James J. HickmanHedvika Davis
    • A61K35/30A61P25/00C12N5/079
    • C12N5/0622C12N2500/90C12N2501/01C12N2501/11C12N2501/115C12N2501/135C12N2501/70C12N2501/81C12N2501/91C12N2506/025C12N2506/1369C12N2506/1392
    • The invention provides a method of producing oligodendrocytes by in vitro differentiation of human multi-potent progenitor cells (MLPCs). The method comprises culturing isolated MLPCs on a first surface in a serum-free defined culture medium; replacing the culture medium with serum-free culture medium supplemented with bFGF, EGF and PDGF-AA for approximately 24 hours; changing the cultured MLPCs into the supplemented serum-free culture medium further supplemented with differentiation factors norepinephrine, forskolin. and K252a; establishing a 3D environment by covering the culture with a second surface opposite and spaced apart from the first surface, so as to contain the MLPCs therebetween; and continuing to culture until a majority of the MLPCs have differentiated into oligodendrocytes. Additionally included is a method of treatment for a subject afflicted by a disease characterized by central or peripheral nervous system demyelination, the method comprising transplanting into the subject oligodendrocytes produced according to the method disclosed.
    • 本发明提供了通过体外分化人多能祖细胞(MLPC)产生少突胶质细胞的方法。 该方法包括在无血清定义培养基的第一表面培养分离的MLPC; 用补充有bFGF,EGF和PDGF-AA的无血清培养基代替培养基约24小时; 将培养的MLPC变成补充的无血清培养基,进一步补充分化因子去甲肾上腺素,毛喉素。 和K252a; 通过用与第一表面相对且间隔开的第二表面覆盖培养来建立3D环境,以便在其间容纳MLPC; 并继续培养,直到大多数MLPC已经分化为少突胶质细胞。 另外包括治疗由以中枢神经系统或周围神经系统脱髓鞘为特征的疾病所折磨的受试者的方法,该方法包括将根据所公开的方法产生的少突胶质细胞移植到受试者中。